Evangelos K Oikonomou1, Marc A Suchard2,3, Darren K McGuire4, Rohan Khera1,5. 1. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. 2. Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA. 3. Departments of Computational Medicine and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. 4. University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas, TX. 5. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Abstract
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardioprotective effects but are underused, partly because of high cost. We aimed to develop a machine learning-based decision support tool to individualize the atherosclerotic cardiovascular disease (ASCVD) benefit of canagliflozin in type 2 diabetes. RESEARCH DESIGN AND METHODS: We constructed a topological representation of the Canagliflozin Cardiovascular Assessment Study (CANVAS) using 75 baseline variables collected from 4,327 patients with type 2 diabetes randomly assigned 1:1:1 to one of two canagliflozin doses (n = 2,886) or placebo (n = 1,441). Within each patient's 5% neighborhood, we calculated age- and sex-adjusted risk estimates for major adverse cardiovascular events (MACEs). An extreme gradient boosting algorithm was trained to predict the personalized ASCVD effect of canagliflozin using features most predictive of topological benefit. For validation, this algorithm was applied to the CANVAS-Renal (CANVAS-R) trial, comprising 5,808 patients with type 2 diabetes randomly assigned 1:1 to canagliflozin or placebo. RESULTS: In CANVAS (mean age 60.9 ± 8.1 years; 33.9% women), 1,605 (37.1%) patients had a neighborhood hazard ratio (HR) more protective than the effect estimate of 0.86 reported for MACEs in the original trial. A 15-variable tool, INSIGHT, trained to predict the personalized ASCVD effects of canagliflozin in CANVAS, was tested in CANVAS-R (mean age 62.4 ± 8.4 years; 2,164 [37.3%] women), where it identified patient phenotypes with greater ASCVD canagliflozin effects (adjusted HR 0.60 [95% CI 0.41-0.89] vs. 0.99 [95% CI 0.76-1.29]; Pinteraction = 0.04). CONCLUSIONS: We present an evidence-based, machine learning-guided algorithm to personalize the prescription of SGLT2 inhibitors for patients with type 2 diabetes for ASCVD effects.
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardioprotective effects but are underused, partly because of high cost. We aimed to develop a machine learning-based decision support tool to individualize the atherosclerotic cardiovascular disease (ASCVD) benefit of canagliflozin in type 2 diabetes. RESEARCH DESIGN AND METHODS: We constructed a topological representation of the Canagliflozin Cardiovascular Assessment Study (CANVAS) using 75 baseline variables collected from 4,327 patients with type 2 diabetes randomly assigned 1:1:1 to one of two canagliflozin doses (n = 2,886) or placebo (n = 1,441). Within each patient's 5% neighborhood, we calculated age- and sex-adjusted risk estimates for major adverse cardiovascular events (MACEs). An extreme gradient boosting algorithm was trained to predict the personalized ASCVD effect of canagliflozin using features most predictive of topological benefit. For validation, this algorithm was applied to the CANVAS-Renal (CANVAS-R) trial, comprising 5,808 patients with type 2 diabetes randomly assigned 1:1 to canagliflozin or placebo. RESULTS: In CANVAS (mean age 60.9 ± 8.1 years; 33.9% women), 1,605 (37.1%) patients had a neighborhood hazard ratio (HR) more protective than the effect estimate of 0.86 reported for MACEs in the original trial. A 15-variable tool, INSIGHT, trained to predict the personalized ASCVD effects of canagliflozin in CANVAS, was tested in CANVAS-R (mean age 62.4 ± 8.4 years; 2,164 [37.3%] women), where it identified patient phenotypes with greater ASCVD canagliflozin effects (adjusted HR 0.60 [95% CI 0.41-0.89] vs. 0.99 [95% CI 0.76-1.29]; Pinteraction = 0.04). CONCLUSIONS: We present an evidence-based, machine learning-guided algorithm to personalize the prescription of SGLT2 inhibitors for patients with type 2 diabetes for ASCVD effects.
Authors: Dirk Sibbing; Dániel Aradi; Claudius Jacobshagen; Lisa Gross; Dietmar Trenk; Tobias Geisler; Martin Orban; Martin Hadamitzky; Béla Merkely; Róbert Gábor Kiss; András Komócsi; Csaba A Dézsi; Lesca Holdt; Stephan B Felix; Radoslaw Parma; Mariusz Klopotowski; Robert H G Schwinger; Johannes Rieber; Kurt Huber; Franz-Josef Neumann; Lukasz Koltowski; Julinda Mehilli; Zenon Huczek; Steffen Massberg Journal: Lancet Date: 2017-08-28 Impact factor: 79.321
Authors: Antonio Ceriello; Eberhard Standl; Doina Catrinoiu; Baruch Itzhak; Nebojsa M Lalic; Dario Rahelic; Oliver Schnell; Jan Škrha; Paul Valensi Journal: Diabetes Care Date: 2020-05-14 Impact factor: 19.112
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler Journal: N Engl J Med Date: 2020-09-24 Impact factor: 91.245
Authors: Eric T Wittbrodt; James M Eudicone; Kelly F Bell; Devin M Enhoffer; Keith Latham; Jennifer B Green Journal: Am J Manag Care Date: 2018-04 Impact factor: 2.229
Authors: Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Terrance D Barrett; Michele Weidner-Wells; Hsiaowei Deng; David R Matthews; Bruce Neal Journal: Lancet Diabetes Endocrinol Date: 2018-06-21 Impact factor: 32.069
Authors: Christian Ott; Agnes Jumar; Kristina Striepe; Stefanie Friedrich; Marina V Karg; Peter Bramlage; Roland E Schmieder Journal: Cardiovasc Diabetol Date: 2017-02-23 Impact factor: 9.951
Authors: Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal Journal: Circulation Date: 2018-07-31 Impact factor: 29.690